Stay up-to-date with all the local and international news from the HARTMANN GROUP.

In the first half of 2020, HARTMANN achieved strong organic sales growth of 16 percent and a significant improvement in earnings. The high demand for products to cope with the corona pandemic compensated for the Corona-related decline in other business areas. HARTMANN has therefore decided to raise its forecast for 2020. Detailed information can be found in the half-year report.

The coronavirus pandemic continued to dominate the second quarter of 2020. “During the coronavirus pandemic, the HARTMANN GROUP has lived up to its important responsibility as a company in the healthcare sector. In particular, we have largely been able to meet the increased demand for disinfectants and personal protective equipment, by making appropriate use of resources to increase production and expand sources of supply for individual product groups,” says Britta Fünfstück, CEO of the HARTMANN GROUP.

The coronavirus pandemic was the defining issue for the HARTMANN GROUP in the first quarter of 2020. The business was strengthened during the period as a result of increased customer demand for disinfectants and protective equipment, as well as intensive measures to increase production capacities and the procurement of supplies despite difficulties in supply markets. HARTMANN recorded strong organic sales growth of 11.9% and a significant improvement in results as compared to the same period in the previous year. Sales revenues were at a total of EUR 603.5 million, and adjusted EBITDA was at EUR 73.6 million.

Stefan Müller takes over the position of Chief Financial Officer (CFO) at PAUL HARTMANN AG as of July 1, 2020. The new CFO has many years of experience as CFO in various areas at ZEISS in Germany and the USA

Against the backdrop of the expected moderate sales growth, EBIT declined to EUR 104.4 million (previous year: EUR 123.2 million), in line with the forecast range. The challenges with respect to the earnings performance are strongly related to the difficult macroeconomic conditions within the markets as well as extensive regulatory requirements. In order to counteract this challenging earnings trend, HARTMANN initiated a comprehensive, five-year strategic transformation programme in 2019.

Focus on innovative strength, competitive strength and process efficiency.
The HARTMANN GROUP is starting to implement a new five-year strategic program to strengthen its competitiveness and secure a leading international market position in the three core segments of Wound, Incontinence and Infection Management.

HARTMANN Group, a leading international supplier of medical and hygiene products, announces the acquisition of Safran Coating. The silicone coating specialist joins HARTMANN’s Wound Management team and positions HARTMANN to better serve patients by expanding its offering in advanced wound care (AWC).

The HARTMANN GROUP, one of the leading international suppliers of medical and hygiene products, increased sales revenues by 3.7% to EUR 1.075 billion in the first half of 2019. All segments generated higher sales. The Wound Management segment has developed particularly dynamically. The Wound Management segment was an additional growth factor. With innovative wound care treatment concepts, we were able to exceed the average sales growth achieved by the HARTMANN GROUP. EBIT declined overall to EUR 53.4 million (previous year: EUR 61.1 million), a development attributable in particular to the anticipated rise in the price of important raw materials and exchange rate trend.

In the first three months of 2019, the HARTMANN GROUP, one of the leading international suppliers of medical and hygiene products, increased its sales revenues by 4.0% to EUR 536.4 million. The key growth drivers were the Wound Management segment and the CMC and KNEIPP brands that are included in the Other Group Activities segment. EBIT amounted to EUR 30.6 million which was virtually the same last year’s figure of EUR 31.3 million. As expected, the higher prices of raw materials in particular had an adverse impact.

The HARTMANN GROUP has coped well with the global market challenges during the 2018 financial year. Despite an unfavorable exchange rate development, persistently high regulatory expenses and increasing pressure on prices and margins across the industry, an increase in sales of 2.9 % and, influenced by these challenges, an EBIT of EUR 123.2 million were achieved.

From January to September 2018, the HARTMANN GROUP, a leading international supplier of medical and hygiene products, increased group sales to EUR 1,563.9 million, despite difficult market conditions. This reflects a moderate increase of 3.2 percent compared to the previous year.

The Supervisory Board of the HARTMANN GROUP today announced the appointment of Britta Fuenfstueck as the company’s new Chief Executive Officer and Chair of HARTMANN’s Management Board. Fuenfstueck will succeed Andreas Joehle, who has been in office since 2013 and announced last year his plans to step down due to personal reasons. She will join the Management Board of HARTMANN on November 1, 2018 and will succeed Joehle as CEO on January 1, 2019.

The HARTMANN GROUP made a positive start in its anniversary year, 2018. Propelled by innovative product solutions and LINDOR's sales in the incontinence management segment, the Group's sales revenues rose to €516.0 million in the first quarter of 2018, an increase of 2.3 percent compared to the previous year. Without the negative impact of adverse exchange rates in America and Asia due to the strength of the euro, the rise in sales would have amounted to around 4 percent. Earnings before interest and taxes (EBIT) were in line with expectations at €31.3 million.

More than 50 percent of nurses in Germany are thinking of leaving their jobs due to the current professional environment. This has been revealed by the HARTMANN GROUP’s Pflexit-Monitor, provider of medical and nursing products. The company will be supporting the German Nursing Day from March 15-17, 2018.

"With targeted investments in the future and holistic healthcare solutions, we were able to increase Group sales by 3.6% during the 2017 financial year to €2.06 billion. This means we are building on the growth rates of previous years," explains Andreas Joehle, Chief Executive Officer of the HARTMANN GROUP.

Heidenheim/Germany, November 7, 2017. In the first nine months of 2017, the HARTMANN GROUP, a leading international supplier of medical and healthcare products, succeeded in increasing its group sales revenues to EUR 1,514.7 million, a rise of 3.2% in relation to the prior year, despite difficult market conditions.

Heidenheim/Germany, September 4, 2017. Recognized for their remarkable contributions in wound care, the nominees for HARTMANN’s first LINK® Award were announced in anticipation of the LINK® Wound Healing Congress on Sept. 19th in Belfast. The congress will give health care professionals the opportunity to network and exchange knowledge on wound care.

Heidenheim/ Germany, August 9, 2017. In the first six months of 2017, the HARTMANN GROUP, a leading international supplier of medical and healthcare products, achieved sales revenues of EUR 1,006.8 million and exceeded the prior-year figure by 3.4%, thus passing the one billion mark for the first time ever within a half-year period. As expected, growth in the second quarter was more restrained, due to among other things, changes in product range, connected with pending market launches within the Incontinence Management segment. Because of investments in growth, as reflected in particular in the greater expenditure for sales and marketing and the higher cost of raw materials and expenses for regulatory issues, the earnings before interest and taxes (EBIT) were slightly lower at EUR 65.4 million (prior year: EUR 68.6 million). The Group's consolidated net income of EUR 45.4 million is nevertheless at the same level as last year (EUR 45.3 million).